Patricia Walker - Concepedia

Author

Patricia Walker

Also Known As

C Devireddy, Ederson Roberto de Mattos, Everhart, James E., P A Walker, P Walker, P. Walker, PA Walker, PATRICIA WALKER, Patricia A Walker, Patricia A. Walker

161

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Monash University Vita-Salute San Raffaele University Peninsula Health IRCCS Ospedale San Raffaele Alfred Health

About

Patricia Walker is an author at Monash University specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	2.5K
2	Health Sciences	8	8	1K
3	Public Health	3	3	50
4	Allergy	1	1	333
5	Emergency Medicine	1	1	10

Patricia Walker

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study Naga Chalasani, Herbert L. Bonkovsky, Robert J. Fontana, Gastroenterology Dilin Prospective StudyHepatologyMedicineLiver PhysiologyGastroenterology	2015	872
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology	2020	583
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial Eitan Kerem, Michael W. Konstan, K. De Boeck, The Lancet Respiratory Medicine AllergyPlacebo-controlled Phase 3Clinical TrialsNonsense-mutation Cystic FibrosisMedicine	2014	333
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaZanubrutinib Versus BendamustineMedicineHematology	2022	256
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell, The Lancet Respiratory Medicine MedicineHypertonic SalineDornase AlfaPulmonary Fibrosis	2022	116
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Haematologica	2020	101
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome Puay Hoon Tan, Andrew H. Wei, Sridurga Mithraprabhu, Blood Cancer Journal	2014	95
Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients Chindu Govindaraj, Peter Tan, Patricia Walker, Clinical Cancer Research	2013	79
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases Sumita Ratnasingam, Patricia Walker, Huy Tran, Blood Advances Proteasome InhibitorsImmunologyImmunotherapyHematological MalignancyThrombosis	2016	71
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Jeff P. Sharman, Versha Banerji, Laura Fogliatto, Blood	2019	61

Page 1